Mirtazapina Teva (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2, 5‑HT3 and H1 receptors. This combined effect enhances serotonergic and noradrenergic neurotransmission, contributing to its antidepressant activity.

The appropriate dose of Mirtazapina Teva is determined by the prescribing clinician based on the patient’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for mirtazapine in pregnancy and lactation are limited, and the medication should only be used if the potential benefit justifies any potential risk to the fetus or infant. Consultation with a healthcare professional is essential before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. It often causes sedation and weight gain, which can be advantageous for patients with insomnia or loss of appetite, whereas other antidepressants may have different side‑effect profiles.

Mirtazapina Teva should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date.

Mirtazapina Teva is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe hypotension, seizures, hepatic dysfunction, and the emergence or worsening of suicidal thoughts, particularly during the initial weeks of therapy. Patients should be monitored closely for any unusual symptoms.

Mirtazapina Teva is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in those currently taking monoamine oxidase inhibitors. Caution is advised for individuals with severe hepatic impairment, uncontrolled hypertension, or a history of bipolar disorder.